

Electronic Acknowledgement Receipt

EFS ID:	4906379
Application Number:	09322289
International Application Number:	
Confirmation Number:	7773
Title of Invention:	PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES
First Named Inventor/Applicant Name:	DALE B. SCHENK
Customer Number:	20350
Filer:	Rosemarie L. Celli/Tina Trieu
Filer Authorized By:	Rosemarie L. Celli
Attorney Docket Number:	15270J-004740US
Receipt Date:	04-MAR-2009
Filing Date:	28-MAY-1999
Time Stamp:	19:46:39
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	5526
Deposit Account	201430
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		15270J-004740US_SIDS_02-04-09.PDF	518797 b6d50bdccf2b623bb6da0a72371281a283930b32	yes	13
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Information Disclosure Statement (IDS) Filed (SB/08)		1	8	
	Information Disclosure Statement (IDS) Filed (SB/08)		9	13	
Warnings:					
Information:					
2	Foreign Reference	1102-EP1690547A1.pdf	705480 1009779bfaa3970bd1490751a097ae76258f44fd	no	60
Warnings:					
Information:					
3	Foreign Reference	1135-08131298_repub.pdf	208262 8d109888a40d90a738841c12c0a304785f057de8	no	4
Warnings:					
Information:					
4	Foreign Reference	1107-WO2008131298.pdf	4159538 3af1fae93a75348cc9db7bf2063030e9bd456d5b	no	87
Warnings:					
Information:					
5	Foreign Reference	1133-WO06042158A2A3.pdf	3541579 a20abe0b12f13f5f9c1fb658412ce8ad11692fa4	no	64
Warnings:					
Information:					
6	Foreign Reference	1146-WO05035753.pdf	4814834 8648315185fa7da3ebc436e434a4e2031f607ada	no	143
Warnings:					
Information:					

7	Foreign Reference	1145-WO87002671.pdf	4461100	no	129
			47be3bfd06a959643070fb415c5885e1bc0d6e8f		
Warnings:					
Information:					
8	NPL Documents	1120-ArmourRecombinantHumanIgG_1999.pdf	991519	no	12
			a1fa47278017cacd82680aa4839b46a17b878952		
Warnings:					
Information:					
9	NPL Documents	1117-Remington17thparenteral.pdf	311786	no	5
			ab2a84f03bc81ca9e5a925595b004dd52ffd5235		
Warnings:					
Information:					
10	NPL Documents	1138-Brinkman_SpliceVariants_2004.pdf	813327	no	11
			f27a10b055ec505363d87f146f38b9c8895fe6f4		
Warnings:					
Information:					
11	NPL Documents	1110-Chen_SelectionandAnalysis_1999.pdf	1334255	no	17
			5020fa57070111c8a4c53ecc8eae8041718c3134		
Warnings:					
Information:					
12	NPL Documents	1142-Choi_AGenericIntron_1991.pdf	457474	no	5
			9bc13454648ad410491efc480481dc66dbb14c41		
Warnings:					
Information:					
13	NPL Documents	1132-Corcoran_Overexpression.pdf	992540	no	10
			a95262d5af555daf918d7fe8d9db5bb8e77db575		
Warnings:					
Information:					
14	NPL Documents	1144-database_Nucleotide_2005.pdf	75969	no	2
			9fd8f80a577ba1bdd22db5067600d2553bc5fd8		
Warnings:					
Information:					
15	NPL Documents	1100_DerwentRecord_1995-261292.pdf	97516	no	3
			e9f50d207535c7fddc3652c0b5c4fc3c8a495410		
Warnings:					
Information:					

16	NPL Documents	1137_ExtendedEPOSearch_058 124366_12-18-08.pdf	612214	no	13
			c61705e9b35b5b2fb34dc8e032e98d961ad869f6		
Warnings:					
Information:					
17	NPL Documents	1136-SupplEPSearch_047762520_09-23-08.pdf	247188	no	6
			339fd93939698a54d8a26186e693d0a593e930f6		
Warnings:					
Information:					
18	NPL Documents	1130-EPcommunicationfor04720353_4_12-8-00.pdf	646846	no	6
			6b242f5f775f8c95d8714932fc0bfc92b47c4f0c		
Warnings:					
Information:					
19	NPL Documents	1134-EPOExam_080114093_11_20_08.pdf	512921	no	14
			3dfc760a62d3b9e6cc2d2c36942442f8f11b795c		
Warnings:					
Information:					
20	NPL Documents	1150-InpadocFileof_EP0613007.pdf	75361	no	4
			2184babdee0f2c970d6b1dbc6c6af9db15d21f95		
Warnings:					
Information:					
21	NPL Documents	1097-FragioneB_abstract_FamiliaCerebralAmyloid_2001.PDF	57789	no	1
			24656a992a0973ea78bb4702a9d11bd86f32b64f0		
Warnings:					
Information:					
22	NPL Documents	1118-Hazareh_EffectiveFunctionActivities.pdf	828888	no	8
			4d9f7d15bd60885cf553d8b236d53cb10ead9164		
Warnings:					
Information:					
23	NPL Documents	1127-Janeway_Immunobio_1997.pdf	913722	no	5
			d87e12098e82009b7316e44af78eecdac7807e1		
Warnings:					
Information:					
24	NPL Documents	1121-Mann_Atypica_Amyloid1996.pdf	948363	no	8
			94cac44286af7dd663e32363910792b06be1f83e		
Warnings:					
Information:					

25	NPL Documents	1122-Mann_Predomdepo1996.pdf	1918572	no	10
			5c66b7a3ca9e80d03aab0fe1ab86e4fbd3dd27c2		
Warnings:					
Information:					
26	NPL Documents	1139-Myers_targetingImmune_2002.pdf	1198330	no	13
			04fbd24dff9e72e67fb905c07fac99277fbce0cc		
Warnings:					
Information:					
27	NPL Documents	1108-Pascalis_GraftingAbbreviatedComplementarity_2002.pdf	934189	no	9
			8b95e3a6e88019d73149ebccbed91fa627b9cd66		
Warnings:					
Information:					
28	NPL Documents	1149-Qu_AB42GeneVaccine_AB42Depo_2007.pdf	2077916	no	10
			a0c604820321a333bbf920903157620182497b5c		
Warnings:					
Information:					
29	NPL Documents	1141-Robbins_TheIntronic_1997.pdf	506425	no	6
			b2733c7f568f1b9e36c35584dd01f4faddb415bd		
Warnings:					
Information:					
30	NPL Documents	1140-Seabrook_SpeciesSpecific_2004.pdf	860603	no	11
			ad5a7ab61fbc61281bb6d127e6efbb8e0d116f9		
Warnings:					
Information:					
31	NPL Documents	1123-Schmidt_Monoclonal_Antibody_1997.pdf	871874	no	12
			59e97c8ac3892fde681bdfea26630afc879a3ade		
Warnings:					
Information:					
32	NPL Documents	1119-Sherpherd_APracticalApp_2000.pdf	528527	no	8
			162ed6be8a89cc7af3261075b2b85fa4c0113407		
Warnings:					
Information:					
33	NPL Documents	1104-Sidhu_PageDisplayinPharmaceutical_2000.pdf	746671	no	7
			7abb327a28ddb8250a2dd88981e89b79286a8980		
Warnings:					
Information:					

34	NPL Documents	1105-Smith_PhageDisplay_1997.pdf	2280879	no	20
			f7b0e6953a40e24f65b365abfd8bb6207599af12c		
Warnings:					
Information:					
35	NPL Documents	1128-Studnicka_abstract.pdf	101480	no	2
			ed78095028d8547822c7146a4017cae2c464472b		
Warnings:					
Information:					
36	NPL Documents	1124-Tamaoka_Antibodto_amyloid1996.pdf	862086	no	10
			7a2ea95d48302a6a4370a4c20cd93a7a7e69551b		
Warnings:					
Information:					
37	NPL Documents	1112-09316387_FinalOfficeAction_09-10-07.pdf	555162	no	15
			a540d530fa335dd737cdfff50749407bfabe308e		
Warnings:					
Information:					
38	NPL Documents	1113-09316387_RespToOAFiled_12-20-2005.pdf	525300	no	16
			f4b581a354a72e9959795038fb3ed7fa9ce8769f		
Warnings:					
Information:					
39	NPL Documents	1114-US09316387_DeclOfSolomonHrncicWall_03-06-2006.pdf	340260	no	7
			20cec740495f9e314a5bbe123f8e314b214dfae		
Warnings:					
Information:					
40	NPL Documents	1115-US09316387_OAmailed_06-20-2005.pdf	1210599	no	29
			6957e81883c6f21b0a5ee7ee290d83f0b256930a		
Warnings:					
Information:					
41	NPL Documents	1109-Vajdos_ComprehensiveFunctionalMaps_2002.pdf	1145757	no	14
			886b74ac305f08db83ba89d755db74bf672a6527		
Warnings:					
Information:					
42	NPL Documents	1143-Ward_SpontaneousDeletions_1991.pdf	470487	no	6
			221521679318ec35f15b73a2e5019ad9e42401b0		
Warnings:					
Information:					

43	NPL Documents	1106- Wilson_PhageDisplayApplications_1998.pdf	1810382 5fc0e375c1ef4b8b06df9ba8b0b8ef3f99303e58	no	17
Warnings:					
Information:					
44	NPL Documents	1111- Wu_HumanizationofMurine_1999.pdf	1090938 417831024783d5e3b418d38025098870f91aeeccb	no	12
Warnings:					
Information:					
45	NPL Documents	1125- Yanagisawa_Amyloid_BETA1997.pdf	468603 2326584f01a827e874d7cdc7d729f37c83c655c5	no	4
Warnings:					
Information:					
46	NPL Documents	1126-Yang_MonoAntibody1994.pdf	564236 68a516cf36d7316599f947b6eb59b7b11f138d4b	no	4
Warnings:					
Information:					
47	Fee Worksheet (PTO-06)	fee-info.pdf	30539 7d9ccac504419a2d794ad057b9ed8fe23146fe05	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			49427083		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					